We Offer Worldwide Shipping
Login Wishlist

Soyasaponin I


Catalogue Number : BF-S4006
Specification : 95%(HPLC)
CAS number : 51330-27-9
Formula : C48H78O18
Molecular Weight : 943.12
PUBCHEM ID : 122097
Volume : 25mg

In stock

Checkout Bulk Order?

Catalogue Number


Analysis Method






Molecular Weight




Botanical Source

Trigonella foenum-graecum,Abrus pulchellus subsp. cantoniensis,Astragalus membranaceus,Glycine max

Structure Type






(2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-5-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid


(2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-5-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid


1.4±0.1 g/cm3


Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

291.2±27.8 °C

Boiling Point

1024.2±65.0 °C at 760 mmHg

Melting Point



InChl Key


WGK Germany


HS Code Reference


Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:51330-27-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate




Scope: Obesity is linked to a chronic low-grade inflammatory state that contributes to the development of obesity-associated metabolic disorders. The anti-inflammatory activities and mechanisms of soyasaponin monomers (A1 , A2 , and I) have been recently demonstrated in cell models. However, their potential in vivo abilities to reduce chronic inflammation and alleviate metabolic disorders in obese status remain unclear.

Methods and results: High fat diet (HFD)-fed obese male C57BL/6J mice are intervened by aspirin (0.1 mg kg-1 body weight) or 20 mg kg-1 of soyasaponins A1 , A2 , or I for 8 weeks. Soyasaponins A1 , A2 , and I significantly reduce pro-inflammatory cytokines/mediators in serum, liver, and white adipose tissues (WATs), improve serum lipid profiles, decrease liver cholesterol, triglyceride and steatosis, and promote fecal excretion of cholesterol, triglycerides, and bile acids. Soyasaponins A1 , A2 , and I also decrease IKKα/β phosphorylation in liver and WATs and reduce NF-κB p65 phosphorylation and CD68 mRNA and protein expression in WATs. Soyasaponins A1 and A2 but not I decrease NF-κB p65 phosphorylation in liver and adipocytes hypertrophy in WATs. In addition, Soyasaponin A2 but not A1 nor I decreases fasting blood glucose and improved insulin resistance.

Conclusion: Soyasaponins reduce inflammation and improve serum lipid profiles and glucose homeostasis in HFD-induced obese mice.


anti-inflammation; hypoglycemic activity; obesity; serum lipid profiles; soyasaponin.


Soyasaponins Reduce Inflammation and Improve Serum Lipid Profiles and Glucose Homeostasis in High Fat Diet-Induced Obese Mice


Qunying Xie 1, Xiangfu Gu 1, Junbin Chen 1, Minshun Liu 1, Fei Xiong 1, Xinglong Wu 1, Yajie Zhang 1, Fengping Chen 1, Honger Chen 1, Meijuan Li 1, Suxia Sun 1, Xinwei Chu 1, Longying Zha 1

Publish date

2018 Oct;




Key message Significant QTL for soyasaponin I, as the major component of the soyasaponin B, have been identified using an RIL soybean population, which could facilitate the development of functional food soybean cultivars. Soyasaponin B forms that are naturally found in soybean (Glycine max [L.] Merr.) seed, have been of interest to the food industry because of their functional food properties. The predominant form soyasaponin B is soyasaponin I. While some of the genes in the biosynthesis of soyasaponins have been characterized, the underlying genetics of soyasaponins as a quantitative trait is still poorly understood. The objective of this study was to identify quantitative trait loci (QTL) associated with the accumulation of soyasaponin I using a genetic mapping population. The population consisting of 186 F4:7 recombinant inbred lines derived from the cross of ‘OAC Glencoe’ and ‘OAC Wallace’ was grown in two Southern Ontario locations in 2015 and 2016. The concentration of soyasaponin I was determined using high-performance liquid chromatography. Putative QTL associated with the accumulation of soyasaponin I were identified through simple interval mapping and composite interval mapping on chromosomes 10 and 16, which explained up to 11% of the total phenotypic variation per QTL for the trait. A significant positive correlation was observed between soyasaponin I and seed protein concentration in the mapping population, which may be advantageous for the development of soybean lines with improved soyasaponin I profiles. QTL identified in this study may facilitate marker-assisted selection for the development of food-grade soybean lines with improved functional properties.


Identification of quantitative trait loci associated with soyasaponin I concentration in soybean seed


Edward C MacDonell 1, Istvan Rajcan 2

Publish date

2018 Oct;




Objective: Our previous study has shown that high expression of α2,3-sialytransferase type I was associated with advanced stage serous type epithelial ovarian cancer (EOC). The aim of the current study further attempts to evaluate the altered α 2,3-sialylation on the behavior of clear cell type EOC (C-EOC).

Materials and methods: Immunohistochemistry staining, bioinformatics analysis and tissue array were used to disclose the clinical significance of over α2,3-sialylation in C-EOC. An α2,3 sialylation inhibitor, soyasaponin I (SsaI) was used to investigate the behavior change of the C-EOC cell line.

Results: We reconfirmed that α2,3-sialylation, instead of α2,6- sialylation, was associated with late-stage C-EOC. Soyasaponin I could inhibit α2,3-sialylation of C-EOC cell lines and increase E-cadherin expression with subsequently suppressing migration of C-EOC cells.

Conclusions: The current study demonstrated the important role of α2,3-linked sialylation in C-EOC and targeting of α2,3-linked sialylation might offer as a potential therapeutic strategy in the future.


Clear cell type; E-cadherin; Epithelial ovarian cancer; Soyasaponin I; α2,3-sialylation.


The role of α2,3-linked sialylation on clear cell type epithelial ovarian cancer


Pi-Lin Sung 1, Kuo-Chang Wen 1, Huann-Cheng Horng 2, Chia-Ming Chang 3, Yi-Jen Chen 1, Wen-Ling Lee 4, Peng-Hui Wang 5

Publish date

2018 Apr;